SELLAS Life Sciences Group (SLS) Cash from Operations: 2010-2024
Historic Cash from Operations for SELLAS Life Sciences Group (SLS) over the last 15 years, with Dec 2024 value amounting to -$35.4 million.
- SELLAS Life Sciences Group's Cash from Operations fell 13.26% to -$7.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$33.1 million, marking a year-over-year decrease of 4.21%. This contributed to the annual value of -$35.4 million for FY2024, which is 12.71% down from last year.
- According to the latest figures from FY2024, SELLAS Life Sciences Group's Cash from Operations is -$35.4 million, which was down 12.71% from -$31.4 million recorded in FY2023.
- In the past 5 years, SELLAS Life Sciences Group's Cash from Operations ranged from a high of -$10.4 million in FY2020 and a low of -$35.4 million during FY2024.
- Its 3-year average for Cash from Operations is -$30.2 million, with a median of -$31.4 million in 2023.
- As far as peak fluctuations go, SELLAS Life Sciences Group's Cash from Operations spiked by 40.96% in 2020, and later slumped by 149.79% in 2021.
- Yearly analysis of 5 years shows SELLAS Life Sciences Group's Cash from Operations stood at -$10.4 million in 2020, then plummeted by 149.79% to -$26.0 million in 2021, then rose by 8.50% to -$23.8 million in 2022, then crashed by 31.92% to -$31.4 million in 2023, then declined by 12.71% to -$35.4 million in 2024.